Logo image of EPRX

EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Price, Quote, News and Overview

NASDAQ:EPRX - Nasdaq - CA29842P1053 - Common Stock - Currency: USD

5.29  -0.29 (-5.2%)

EPRX Quote, Performance and Key Statistics

EUPRAXIA PHARMACEUTICALS INC

NASDAQ:EPRX (7/30/2025, 8:01:51 PM)

5.29

-0.29 (-5.2%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6.2
52 Week Low2.2
Market Cap190.23M
Shares35.96M
Float29.08M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-08 2025-08-08
IPO03-09 2021-03-09


EPRX short term performance overview.The bars show the price performance of EPRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80

EPRX long term performance overview.The bars show the price performance of EPRX in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of EPRX is 5.29 USD. In the past month the price decreased by -9.42%. In the past year, price increased by 105.84%.

EUPRAXIA PHARMACEUTICALS INC / EPRX Daily stock chart

EPRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.43 334.40B
AMGN AMGEN INC 14.52 162.05B
GILD GILEAD SCIENCES INC 14.83 142.75B
VRTX VERTEX PHARMACEUTICALS INC N/A 120.48B
REGN REGENERON PHARMACEUTICALS 12.52 59.88B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 44.31B
ARGX ARGENX SE - ADR 104.34 36.65B
ONC BEONE MEDICINES LTD-ADR 7.68 32.46B
BNTX BIONTECH SE-ADR N/A 26.46B
INSM INSMED INC N/A 19.95B
SMMT SUMMIT THERAPEUTICS INC N/A 19.80B
NTRA NATERA INC N/A 19.25B

About EPRX

Company Profile

EPRX logo image Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.

Company Info

EUPRAXIA PHARMACEUTICALS INC

201-2067 Cadboro Bay Rd.

Victoria BRITISH COLUMBIA CA

Employees: 33

EPRX Company Website

EPRX Investor Relations

Phone: 12505903968

EUPRAXIA PHARMACEUTICALS INC / EPRX FAQ

What is the stock price of EUPRAXIA PHARMACEUTICALS INC today?

The current stock price of EPRX is 5.29 USD. The price decreased by -5.2% in the last trading session.


What is the ticker symbol for EUPRAXIA PHARMACEUTICALS INC stock?

The exchange symbol of EUPRAXIA PHARMACEUTICALS INC is EPRX and it is listed on the Nasdaq exchange.


On which exchange is EPRX stock listed?

EPRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for EUPRAXIA PHARMACEUTICALS INC stock?

9 analysts have analysed EPRX and the average price target is 8.24 USD. This implies a price increase of 55.75% is expected in the next year compared to the current price of 5.29. Check the EUPRAXIA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EUPRAXIA PHARMACEUTICALS INC worth?

EUPRAXIA PHARMACEUTICALS INC (EPRX) has a market capitalization of 190.23M USD. This makes EPRX a Micro Cap stock.


How many employees does EUPRAXIA PHARMACEUTICALS INC have?

EUPRAXIA PHARMACEUTICALS INC (EPRX) currently has 33 employees.


What are the support and resistance levels for EUPRAXIA PHARMACEUTICALS INC (EPRX) stock?

EUPRAXIA PHARMACEUTICALS INC (EPRX) has a support level at 5.05 and a resistance level at 5.29. Check the full technical report for a detailed analysis of EPRX support and resistance levels.


Should I buy EUPRAXIA PHARMACEUTICALS INC (EPRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EUPRAXIA PHARMACEUTICALS INC (EPRX) stock pay dividends?

EPRX does not pay a dividend.


When does EUPRAXIA PHARMACEUTICALS INC (EPRX) report earnings?

EUPRAXIA PHARMACEUTICALS INC (EPRX) will report earnings on 2025-08-08.


What is the Price/Earnings (PE) ratio of EUPRAXIA PHARMACEUTICALS INC (EPRX)?

EUPRAXIA PHARMACEUTICALS INC (EPRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.05).


What is the Short Interest ratio of EUPRAXIA PHARMACEUTICALS INC (EPRX) stock?

The outstanding short interest for EUPRAXIA PHARMACEUTICALS INC (EPRX) is 0.57% of its float. Check the ownership tab for more information on the EPRX short interest.


EPRX Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to EPRX. When comparing the yearly performance of all stocks, EPRX is one of the better performing stocks in the market, outperforming 94.65% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

EPRX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to EPRX. While EPRX has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EPRX Financial Highlights

Over the last trailing twelve months EPRX reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS increased by 17.83% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -89.7%
ROE -91.67%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-6.36%
Sales Q2Q%N/A
EPS 1Y (TTM)17.83%
Revenue 1Y (TTM)N/A

EPRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to EPRX. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners6.15%
Ins Owners19.16%
Short Float %0.57%
Short Ratio12.61
Analysts
Analysts84.44
Price Target8.24 (55.77%)
EPS Next Y5.38%
Revenue Next YearN/A